Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc., a leader in immunotherapeutic cancer treatments, will be featured in a panel discussion on Viral Approaches in Oncology at the upcoming Canaccord Genuity’s Horizons in Oncology Virtual Conference. The company’s CEO, Dr. Matt Coffey, is set to present and partake in one-on-one investor meetings. Oncolytics is advancing in the field with its novel agent pelareorep, which has shown effectiveness in Phase 2 trials and is moving towards further studies with Fast Track designation for metastatic breast and pancreatic cancers.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
